Last reviewed · How we verify
Mirdametinib and Carbamazepine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Mirdametinib and Carbamazepine (Mirdametinib and Carbamazepine) — SpringWorks Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mirdametinib and Carbamazepine TARGET | Mirdametinib and Carbamazepine | SpringWorks Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mirdametinib and Carbamazepine CI watch — RSS
- Mirdametinib and Carbamazepine CI watch — Atom
- Mirdametinib and Carbamazepine CI watch — JSON
- Mirdametinib and Carbamazepine alone — RSS
Cite this brief
Drug Landscape (2026). Mirdametinib and Carbamazepine — Competitive Intelligence Brief. https://druglandscape.com/ci/mirdametinib-and-carbamazepine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab